AVENUE THERAPEUTICS INC
For the period ended Mar 31, 2024. Filed May 15, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 15, 2024
ATXI$0.42-50.7%Stored close · as of Mar 18, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Table of Contents
Form 10‑Q
For the Quarter Ended March 31, 2024
Table of Contents
| Page No. | ||
|---|---|---|
| PART I. FINANCIAL INFORMATION | ||
| Item 1. · Unaudited Condensed Consolidated Financial Statements | ||
| Unaudited Condensed Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023 | 1 | |
| Unaudited Condensed Consolidated Statements of Operations for the three months ended March 31, 2024 and 2023 | 2 | |
| Unaudited Condensed Consolidated Statements of Stockholders’ Equity (Deficit) for the three months ended March 31, 2024 and 2023 | 3 | |
| Unaudited Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2024 and 2023 | 4 | |
| Notes to Unaudited Condensed Consolidated Financial Statements | 5 | |
| Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 11 |
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 15 |
| Item 4. | Controls and Procedures | 15 |
| PART II. OTHER INFORMATION | ||
| Item 1. | Legal Proceedings | 16 |
| Item 1A. | Risk Factors | 16 |
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 16 |
| Item 3. | Defaults Upon Senior Securities | 16 |
| Item 4. | Mine Safety Disclosures | 16 |
| Item 5. | Other Information | 16 |
| Item 6. | Exhibits | 17 |
| Signatures | 18 | |
Unaudited Condensed Consolidated Balance Sheets
($ in thousands, except share and per share amounts)
| March 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $3,194 | $1,783 |
| Prepaid expenses and other current assets | 116 | 67 |
| Total assets | $3,310 | $1,850 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current Liabilities: | ||
| Accounts payable and accrued expenses | $647 | $287 |
| Accounts payable and accrued expenses - related party | 352 | 323 |
| Warrant liability | 413 | 586 |
| Total current liabilities | 1,412 | 1,196 |
| Total liabilities | 1,412 | 1,196 |
| Commitments and contingencies | ||
| Stockholders’ equity (deficit) | ||
| Preferred stock ($0.0001 par value), 2,000,000 shares authorized | ||
| Class A Preferred Stock, 250,000 shares issued and outstanding as of March 31, 2024 and December 31, 2023 | — | — |
| Common stock ($0.0001 par value), 200,000,000 and 75,000,000 shares authorized as of March 31, 2024 and December 31, 2023, respectively | ||
| Common shares, 590,188 and 341,324 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | — | 3 |
| Additional paid-in capital | 98,104 | 92,507 |
| Accumulated deficit | (95,268) | (90,928) |
| Total stockholders’ equity attributed to the Company | 2,836 | 1,582 |
| Non-controlling interests | (938) | (928) |
| Total stockholders’ equity | 1,898 | 654 |
| Total liabilities and stockholders’ equity | $3,310 | $1,850 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.